Pharma Business Week articles from April 2004

Pharma Business Week archives from April 2004

The ribavirin prodrug viramidine has proven safe in healthy volunteers.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- The ribavirin prodrug viramidine has proven safe in healthy volunteers. "Ribavirin, part of the current first-line combination therapy for the treatment of chronic hepatitis C, has side effects - in...

Pilot study shows symptomatic improvement for men with chronic prostatitis.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Results of a pilot study demonstrate that Flomax (tamsulosin hydrochloride) is superior to placebo in treating the severe urinary dysfunction of chronic prostatitis/chronic pelvic pain syndrome...

NDA filed with FDA for nanoparticle-based Abraxane.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- American Pharmaceutical Partners, Inc., (APP, APPX) and American BioScience, Inc., (ABI) announced that ABI has completed the filing of a New Drug Application (NDA) to the U.S. Food and Drug...

FDA approves Sensipar for the treatment of secondary hyperparathyroidism.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Amgen, Inc., (AMGN) announced that the U.S. Food and Drug Administration (FDA) approved Sensipar (cinacalcet HCl) following a priority review. Sensipar, an innovative, first-in-class oral...

Genaera extends alliance IL-9 alliance.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Genaera Corp. (GENR) and the Ludwig Institute for Cancer Research (LICR) announced a 2-year extension of a collaborative agreement on the joint discovery and development of novel genes and proteins as...

Geron Corp. inks agreement for therapeutic cancer-vaccine technology.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Geron Corp. (GERN) and Merix Bioscience, Inc., have executed an agreement under which Geron has acquired the exclusive right to use Merix's platform technology in therapeutic cancer vaccines using the...

First patients dosed in phase II AeroLEF trial for post-surgical pain.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Delex Therapeutics, a specialty pharmaceutical company, announced that the first patients have been dosed in the company's phase II clinical trial of AeroLEF (aerosolized liposome encapsulated fentanyl)...

Lovenox effective in non-ST-elevation acute coronary syndromes, study shows.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- The results of a landmark, 10,027-patient study show that Lovenox (enoxaparin sodium injection) is as effective as unfractionated heparin (UFH) in the treatment of high-risk patients with...

Cloretazine receives Fast Track designation from FDA.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Vion Pharmaceuticals, Inc., (VION) has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for Cloretazine (VNP40101M) in relapsed or refractory acute myeloid leukemia...

Positive results announced for long-term study of Zeatin.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Senetek PLC (SNTK) announced uniformly positive results for its multi-faceted study of the effects of its patented adenine derivative Zeatin on human skin cells. The study, conducted at the...

Manufacture of validation batches for allergy drug completed.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Elite Pharmaceuticals, Inc., (ELI) announced completion of the manufacture of validation batches for a once-a-day product that treats allergies and the symptoms of allergies. The product was...

Oral formulation of Fasudil improves stable angina in study patients.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Schering AG, Germany, (SHR) announced that study patients with stable angina receiving the oral formulation of fasudil showed an improvement in oxygen delivery to the heart. Fasudil, which Schering...

Foradil Certihaler receives first European approval.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- SkyePharma PLC (SKYE, SKP) announced that the Swiss pharmaceutical regulatory authority has approved Foradil Certihaler (formoterol fumarate inhalation powder). Foradil Certihaler was codeveloped by...

LSBC enters research phase for development of atherosclerosis therapeutic.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Large Scale Biology Corp.'s (LSBC) exclusive license agreement with Cincinnati (Ohio) Children's Hospital Medical Center for the development of a drug to treat a leading cause of death in the U.S. has...

Study demonstrates Metadate CD has greater effect than Concerta.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- A study published in the March 2004 online issue of Pediatrics comparing the effects of two extended-release methylphenidate formulations in children with attention deficit hyperactivity disorder (ADHD)...

Company helps hospitals, manufacturers respond to new FDA rules.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- AmerisourceBergen Corporation (ABC), a pharmaceutical services company, said it has the broadest array of solutions to help pharmaceutical manufacturers and hospitals respond to the U.S. Food and Drug...

Positive phase Ib/II clinical trial results reported for Hemospan.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Sangart, Inc., announced positive results from its phase Ib/II clinical trial involving Hemospan (MP4), a hemoglobin-based oxygen carrier designed to serve as an alternative for blood transfusions. ...

Skeletal imaging agent approved by FDA.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Draximage, Inc., the radiopharmaceutical subsidiary of Draxis Health, Inc., (DRAX) (DAX), has received approval from the U.S. Food and Drug Administration (FDA) to produce and market a new formulation...

Hudson licenses radiosensitizer IPdR.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Hudson Health Sciences, Inc., (HHS), a biopharmaceutical company headquartered in San Francisco, California, has licensed IPdR, a radiosensitizer, from Yale University and The Research Foundation of the...

Breast cancer patients switched to Aromasin more likely to remain cancer free.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Post-menopausal breast cancer patients who switched from tamoxifen to Aromasin (exemestane tablets) had a significantly reduced chance of recurrence and increased disease-free survival compared to...

Caelyx demonstrates efficacy, reduced cardiac toxicity.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Schering-Plough Europe reported that results of a randomized phase III clinical study demonstrated that Caelyx (pegylated liposomal doxorubicin hydrochloride) provided comparable efficacy in the...

Epirubicin, vinorelbine, and cisplatin are effective in advanced breast cancer.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Combined epirubicin, vinorelbine, and cisplatin resulted in an 84% objective response rate for patients with advanced breast cancer. "Our objective was to evaluate the activity and safety of the...

Lamivudine helps keep HBV at bay during cancer chemotherapy.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Researchers in Hong Kong have discovered a way to help prevent the reactivation of the hepatitis B virus (HBV) in women who are being treated with chemotherapy for breast cancer. Winnie Yeo, an...

Letrozole extends time to tumor progression in mouse model.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- In a mouse model of human breast cancer, the drug letrozole more effectively extends time to tumor progression than tamoxifen or various combinations and dosing schedules of tamoxifen plus letrozole....

Preoperative treatment with anastrozole reduces need for extensive surgery.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- New data presented at EBCC 2004 indicate that preoperative (neoadjuvant) treatment with anastrozole (Arimidex; AstraZeneca) results in clinically beneficial reductions in tumor volume, extending the...

Results of comparison study favor exemestane for advanced disease.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- The first results from the only Phase III trial to compare tamoxifen with the newer hormone treatment exemestane in advanced breast cancer shows that exemestane is safe, superior, and lengthens...

Avelox shows clinical success for acute exacerbations of chronic bronchitis.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- A new study shows patients with acute exacerbations of chronic bronchitis (AECB) who took a 5-day course of the antibiotic Avelox (moxifloxacin HCl) achieved a greater clinical cure rate than patients...

Factive receives marketing approval in Canada, ready for U.S. launch.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Genome Therapeutics Corp. (GENE) has received marketing approval for Factive (gemifloxacin mesylate) tablets for the treatment of acute bacterial exacerbations of chronic bronchitis from the Therapeutic...

$1.7M award for cardiac safety monitoring and services announced.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- eResearchTechnology, Inc., (eRT) has been awarded studies totaling approximately $1.7 million in cardiac safety monitoring and services from a top 15 global pharmaceutical organization under a...

Biotechnology company announces Form 15 filing.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Protide Pharmaceuticals, Inc., (PPMD) announced the filing of a Form 15 with the U.S. Securities and Exchange Commission (SEC) to terminate registration of Protide Pharmaceuticals' common stock under...

Biotechnology company announces series B financing and new appointments.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Phylogix, Inc., announced that that it has secured $12 million in series B financing. Leading the round were top-tier venture capital firms Radius Ventures, Atlas Venture, Prospect Venture Partners,...

Pharmaceutical companies spend over $900M on cholesterol drugs, study shows.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Pharmaceutical companies allocate an average cross-functional budget of $933 million to support cholesterol-lowering drugs, according to a new study launched by Cutting Edge Information. ...

Nanotechnology drug developer reports key achievement.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- BioSante Pharmaceuticals (BPA) announced key achievements and financial results for the year ended December 31, 2003. "We are quite pleased with our achievements and progress in the last year....

Pharmacogenomics company establishes U.K. subsidiary.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Gene Logic, Inc., (GLGC) has established Gene Logic, Ltd., a wholly owned subsidiary based in the United Kingdom, that will facilitate sales, marketing, and customer support in Europe for the company's...

Commercial agreement announced for cancer vaccine product candidate.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Prima BioMed Ltd, subsidiary CancerVac, and Biomira Inc. (BIOM) announced a commercial agreement for the development and commercialization of CancerVac's most advanced cancer vaccine product candidate....

Pharmaceutical plant workers have no excess mortality.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- A study of pharmaceutical plant employees found no pattern of excess mortality over a 50-year period. "An historical cohort study was conducted of workers at a pharmaceutical manufacturing plant....

Cardiac MRI a better predictor of heart attack, death for women.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- The use of non-invasive cardiac magnetic resonance imaging (MRI) appears to be more effective than conventional diagnostic procedures, such as nuclear stress testing and coronary angiography, in the...

Aloxi injection incorporated into NCCN antiemetic guidelines.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- MGI Pharma, Inc., (MOGN) announced that Aloxi (palonosetron hydrochloride) injection has been incorporated into the 2004 National Comprehensive Cancer Network (NCCN) antiemetic guidelines for prevention...

Database offers secure, long-term storage of chromatography data.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Varian, Inc., (VARI) introduced a new option for its successful Galaxie Chromatography Data System, called the Galaxie DataBase, which offers the option to collect and store chromatographic data in a...

Preliminary results of Xcytrin for chronic lymphocytic leukemia announced.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Pharmacyclics, Inc., (PCYC) announced the presentation of preliminary results from its ongoing, recently initiated, phase II trial evaluating Xcytrin (motexafin gadolinium) Injection as a single agent...

Enrollment status announced for Oxytrex phase III study.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Pain Therapeutics, Inc., (PTIE) has enrolled more than 350 patients in its first phase III study with Oxytrex, an oral painkiller being developed by the company to treat severe chronic pain. "This...

Agreement signed for Canadian distribution of dermatology products.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Atrix Laboratories, Inc., (ATRX) announced that the company has signed an exclusive marketing agreement with Genpharm for the distribution of specific generic topical dermatology products in Canada. ...

Agreement signed with Gilead Sciences for use of Captisol.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- CyDex, Inc., announced that it has entered into a limited use agreement with Gilead Sciences, Inc., for CyDex's advanced formulation system Captisol. Captisol enables the safe, effective delivery of...

Alliance partners to accelerate development of drug-eluting stent.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- CardioTech International, Inc., (CTE) and Implant Sciences Corporation (IMX.WS) jointly announced that they have joined with CorNova, Inc., to develop and market a new generation drug-eluting stent...

Alliance to focus on cancer drug study.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- ChromaVision Medical Systems, Inc., (CVSN), a provider of automated cell-imaging systems and manufacturer of the ACIS digital microscope system, announced that it has entered into a clinical research...

Company expands pipeline to include obesity, oncology therapies.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Gilles Gagnon, president and CEO at AEterna Laboratories, Inc., (AEL; AELA), presented the company's extensive product pipeline in oncology, endocrinology, and infectious diseases at the Bio Square 2004...

Partnership to advance high-tech genomics research.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Children's Memorial Institute for Education and Research and The Translational Genomics Research Institute (TGen), of Phoenix, Arizona, announced a partnership aimed at conducting cutting-edge genomic...

Pharmaceutical firms expand siRNA supply agreement.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Dharmacon, Inc., a supplier of innovative RNA and RNA interference (RNAi) research products, announced an expansion of its existing agreement to supply custom siRNA reagents to Bayer Pharmaceuticals...

Researcher signs siRNA deal to enhance obesity, diabetes program.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- CytRx Corporation (CYTR) said a collaboration recently announced between the University of Massachusetts Medical School (UMMS) and Dharmacon, Inc., will enhance and accelerate the work being done under...

Cancer-care services company announces participation in colon cancer trials.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- A breakthrough treatment for advanced-stage colorectal cancer represents a milestone in research that will have significant benefits for patients, say US Oncology, Inc., (USON), network physicians...

Phase II colorectal vaccine trial results updated.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Biomira, Inc., (BIOM, BRA) provided an update of data from the phase II Theratope vaccine colorectal study of 20 patients. A Kaplan-Meier Survival and Time to Disease Progression Curve of the 20...

Report: Injectable products propel growth in $1.2B aesthetics market.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Medtech Insight, LLC, in a new report entitled "The U.S. Aesthetics Marketplace," details the U.S. markets for surgical and nonsurgical cosmetic surgery products, including topical and injectable...

$1M in grants to fund cytomegalovirus vaccine development.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Vical Incorporated (VICL) has received notification of funding of approximately $1 million for research and development related to the company's plasmid DNA vaccine against cytomegalovirus (CMV) under...

Perindopril reduces cardiovascular death and heart attack risk in diabetes study.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- The long-acting ACE inhibitor perindopril (Coversyl) appears to reduce the risk of cardiovascular death and heart attacks in diabetic patients with stable coronary disease already receiving standard...

Diabetes development in spontaneously diabetic Torii rats described.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Researchers have characterized the development of diabetes in male spontaneously diabetic Torii rats in a recent issue of Biochemical and Biophysical Research Communications. "To characterize the...

IDPc inhibitor has anti-diabetic effects in mice fed high-sucrose diet.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- A synthetic IDPc inhibitor demonstrated anti-diabetic effects in C57BU6J mice fed a high-fat, high-sucrose diet. According to recent research from South Korea, "DA-11004 is a synthetic, potent...

Drug benefits clients beat national drug cost trend.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- A drug trends "scorecard" published by AdvancePCS (ADVP) reveals an impressive tally by health plan sponsors that have aggressively employed pharmacy benefit management tools to slow rising prescription...

Complete genome sequence of Saccharopolyspora erythraea reported.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Aventis Bulk S.p.A. has successfully sequenced the whole genome of Saccharopolyspora erythraea. The strain is an industrial overproducer of erythromycin antibiotic. The work was carried out in...

Collaboration results in initiation of human trials for inflammatory indication.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Pharmacopeia, Inc., (ACCL) announced that Schering-Plough Corporation (SGP) has initiated human trials of a compound for an inflammatory indication discovered through collaboration between the...

Commercial protein purification program to accelerate drug discovery.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Purely Proteins Ltd announced the initiation of its commercial protein purification program designed to accelerate and enhance the drug discovery and development process. The first products from...

Milestone achieved in informatics collaboration.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Tripos, Inc., (TRPS) announced the completion of a significant milestone in its ongoing discovery informatics collaboration with Schering AG. Schering has accepted Tripos' Auspyx data cartridge for...

Weight loss and decreased waist size shown in rimonabant dyslipidemia study.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Results of a phase III clinical trial (RIO-Lipids or Rimonabant In Obesity) comparing rimonabant, the first drug in a new class called selective CB1 blockers (SCB1Bs), to placebo found that overweight...

FDA approves once-daily Floxin Otic (ofloxacin otic solution).
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Daiichi Pharmaceutical Corporation announced the recent approval by the U.S. Food and Drug Administration (FDA) of a once-daily for 7 days dosing regimen of Floxin Otic (ofloxacin otic solution) 0.3%, a...

ADA responds to study citing obesity close to being leading cause of death.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- A new study released by the U.S. Centers for Disease Control and Prevention (CDC) shows that deaths due to poor diet and physical inactivity rose by 33% over the past decade and may soon overtake...

Phenytoin Oral Suspension receives FDA approval for treatment of epilepsy.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Taro Pharmaceutical Industries Ltd. (TARO) reported that its U.S. affiliate has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for...

Majority of patients taking Levitra report satisfaction.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- According to the results of recent survey data, both patients and physicians are reporting satisfaction with the erectile dysfunction treatment Levitra. Ninety-four percent of the 240 surveyed...

Topical therapy can be effective in patients with impotence.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- NexMed, Inc., (NEXM), a developer of transdermal treatments based on the NexACT drug delivery technology, announced that an article positioning Alprox-TD as a potential first choice alternative for...

U.S. orphan drug designation granted for AT1001.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Amicus Therapeutics, Inc., an emerging drug development company focused on the development of a novel therapeutic approach to the treatment of human genetic disorders, with an initial focus on lysosomal...

Autoimmune disease drug maker completes raises $57 million.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Aspreva Pharmaceuticals Corporation announced the completion of a $57 million private equity financing. Sprout Group, one of the oldest and largest U.S. institutional venture capital firms and an...

Bioactive product developer reports 2003 financial results.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Protein Polymer Technologies, Inc., (PPTI) reported financial results for the fourth quarter and the year ended December 31, 2003. For the quarter, the company had a net loss applicable to common...

Bioengineering firm expects record revenue growth, income for 2003.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- American Oriental Bioengineering, Inc., (AOBO) announced that it expects record revenue and net income for the full year 2003. AOBO reported net revenues of $1.12 million for the full year 2002,...

Biopharmaceutical company reports 2003 financial results.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Titan Pharmaceuticals, Inc., (TTP) announced financial results for the fourth quarter and fiscal year ended December 31, 2003. Net loss for fourth quarter 2003 was approximately $10.5 million, or...

Biopharmaceutical firm completes $30M series B financing.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- BioRexis Pharmaceutical Corporation announced that it has raised $30 million in a Series B private equity financing led by Prism Venture Partners of Westwood, Massachusetts, and Quaker BioVentures of...

Biopharmaceutical firm raises $30M in third venture capital round.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- CombinatoRx, Inc., announced that it has raised $30 million in its third venture capital round. The financing includes investments from Boston Millennia Partners, Easton Hunt Capital Partners,...

Biotech company approved for listing on Nasdaq.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Cypress Bioscience, Inc., (CYPB) announced that Cypress' stock has begun trading on the Nasdaq National Market System. Cypress is moving onto the NMS from the Nasdaq Small Cap Market while...

Biotech firm announces conversion of preferred stock into common stock.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- DOR BioPharma, Inc., (DOR) announced that it has completed the conversion of all of its previously outstanding shares of Series B preferred stock into shares of its common stock. The shares of...

Biotechnology company completes $23.1M series B financing.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- VaxInnate Corporation has completed a $23.1 million, series B financing to advance the development of next-generation preventative vaccines and immune therapies for infectious disease and cancer. ...

Diagnostics company announces second closing of private placement.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Avitar, Inc., (AVR) announced that gross proceeds of $1,000,000 were raised in the second closing of the private placement entered into on September 30, 2003. In the second closing, which was...

Immunotherapeutics firm reports quarterly loss of $0.31 per share.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Corixa Corp. (CRXA) announced financial results for the fourth quarter and year ended December 31, 2003. For the fourth quarter of 2003, Corixa reported total revenue of $14.2 million compared with...

Neugene maker reports quarterly loss of $0.10 per share.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- AVI BioPharma, Inc., (AVII) reported financial results for the 3 and 12 months ended December 31, 2003. For the fourth quarter of 2003, AVI reported a net loss of $3.1 million, or $0.10 per share,...

Oncology company files shelf registration statement.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Allos Therapeutics, Inc., (ALTH) announced that it has filed a Form S-3 shelf registration with the U.S. Securities and Exchange Commission (SEC). The shelf registration, when declared effective by...

Oncology company reports record product revenues.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Cytogen Corporation (CYTO) reported its consolidated financial results for the fourth quarter and year ended December 31, 2003. Total revenues for the fourth quarter of 2003 were $3.5 million...

P&G increases third quarter and fiscal year earnings guidance.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- The Procter & Gamble Company (PG) said that earnings per share for the January through March 2004 quarter, as well as the fiscal year, are expected to exceed current consensus estimates by $0.01 to...

Pharmaceutical company announces 2003 financial results.
April 5, 2004... 2004 APR 5 - (NewsRx.com & NewsRx.net) -- Vicuron Pharmaceuticals Inc. (MICU) reported financial results for the fourth quarter and year ended December 31, 2003. For the fourth quarter of 2003, total revenues were $2.8 million compared to...